Business
Non-cystic Fibrosis Bronchiectasis Market Ready to Shift Gears with the Entry of First DPP1 Blocker | DelveInsight
Insmed’s BRINSUPRI (brensocatib) has reached a significant regulatory milestone, earning FDA approval as the first-ever therapy for non-cystic fibrosis bronchiectasis and the first drug targeting DPP1. As the only available treatment in the non-cystic fibrosis bronchiectasis market, this represents both a scientific breakthrough and a pivotal shift in a market long defined by high unmet medical needs.New York, USA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Non-cystic Fibrosis Bronchiectasis Market Ready
About this update from Insmed Incorporated
[{"type":"image","alt":"DelveInsight Business Research LLP","displaySize":"","headline":null,"caption":"DelveInsight Business Research LLP","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":76,"url":"https://media.zenfs.com/en/globenewswire.com/cf9c515e96c3df84627df7d3ec327083"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/I0k6A6Pbgp0fcVuvGiBWCw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/cf9c515e96c3df84627df7d3ec327083","width":300,"height":76}},"lazy":false},{"type":"text","content":"Insmed’s BRINSUPRI (brensocatib) has reached a significant regulatory milestone, earning FDA approval as the first-ever therapy for non-cystic fibrosis bronchiectasis and the first drug targeting DPP1. As the only available treatment in the non-cystic fibrosis bronchiectasis market, this represents both a scientific breakthrough and a pivotal shift in a market long defined by high unmet medical needs.","length":404,"tagName":"p"},{"type":"text","content":"New York, USA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Non-cystic Fibrosis Bronchiectasis Market Ready to Shift Gears with the Entry of First DPP1 Blocker | DelveInsight","length":163,"tagName":"p"},{"type":"text","content":"Insmed’s BRINSUPRI (brensocatib) has reached a significant regulatory milestone, earning FDA approval as the first-ever therapy for non-cystic fibrosis bronchiectasis and the first drug targeting DPP1. As the only available treatment in the non-cystic fibrosis bronchiectasis market, this represents both a scientific breakthrough and a pivotal shift in a market long defined by high unmet medical needs.","length":404,"tagName":"p"},{"type":"text","content":"DelveInsight’s Non-cystic Fibrosis Bronchiectasis Market Report 2034 includes a comprehensive understanding of current treatment practices, emerging non-cystic fibrosis bronchiectasis drugs, market share of individual therapies, and current and forecasted non-cystic fibrosis bronchiectasis market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].","length":437,"tagName":"p"},{"type":"text","content":"Key Takeaways from the Non-cystic Fibrosis Bronchiectasis Market Report","length":71,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"In August 2025, Insmed...